1. Home
  2. DFH vs VIR Comparison

DFH vs VIR Comparison

Compare DFH & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dream Finders Homes Inc.

DFH

Dream Finders Homes Inc.

HOLD

Current Price

$14.08

Market Cap

1.7B

ML Signal

HOLD

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

HOLD

Current Price

$9.06

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFH
VIR
Founded
2008
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.5B
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
DFH
VIR
Price
$14.08
$9.06
Analyst Decision
Hold
Strong Buy
Analyst Count
2
8
Target Price
$26.00
$19.63
AVG Volume (30 Days)
675.2K
2.3M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
17.49
EPS
2.14
N/A
Revenue
$4,322,848,000.00
$68,556,000.00
Revenue This Year
$0.81
N/A
Revenue Next Year
$7.82
$1,049.62
P/E Ratio
$6.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.41
$4.16
52 Week High
$31.10
$10.91

Technical Indicators

Market Signals
Indicator
DFH
VIR
Relative Strength Index (RSI) 36.47 52.52
Support Level N/A $8.67
Resistance Level $14.75 $10.29
Average True Range (ATR) 0.69 0.46
MACD 0.10 -0.09
Stochastic Oscillator 27.45 48.74

Price Performance

Historical Comparison
DFH
VIR

About DFH Dream Finders Homes Inc.

Dream Finders Homes Inc designs, builds and sells homes in markets throughout the United States. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the maximum of its revenue from the Midwest segment.

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

Share on Social Networks: